Latest news with #LosAltos
San Francisco Chronicle
4 days ago
- Sport
- San Francisco Chronicle
How Metro athletes fared at CIF State Track and Field championships
How Metro athletes finish in Saturday's CIF State Track and Field championships in Clovis (Fresno County): METRO MEDALISTS FIRST: Prince Babalola-Buchango (St. Ignatius), 200 (20.79), Kira Gant Hatcher (St. Mary's) triple jump (40-5), Jaden Jefferson (De La Salle), 100 (10.27), Khaliq Muhammad (Pittsburg), pole vault (17-10½), Hanne Thomsen (Montgomery), 3,200 (9:48.98) SECOND: Santia Ali (Clayton Valley), triple jump (39-10¾), Benjamin Bouie (Crystal Springs Uplands), 1,600 (4:04.84), Babalola-Buchango (St. Ignatius), 110 HH (13.59), Maya Ifo Desai (Mitty) girls discus (154-3), El Cerrito boys 4x100 relay (40.72), Landon Pretre (Menlo School), 3,200 (8:54.25), Hannah Rutherford (Mountain View), 400 (54.27), Thomsen (Montgomery), 1,600 (4:35.69) THIRD: St. Francis 4x800 girls relay (8:57.49), Sabrina Zanetto (St. Francis), 800 (2:09.22) More For You Trans athlete embraced as California track and field champion by peers while adult activists duel FOURTH: Avery Boyse (Burlingame) 12-2), Kinga Czajkowska (Palo Alto), 1,600 (4:42.91), De La Salle 4x100 relay (40.80), Jefferson (De La Salle), 200 (20.86), Corinne Jones (St. Mary's), triple jump (38-8½), Ellie McCuskey-Hay (St. Ignatius) long jump (19-3), Rachael Osicka (California), high jump (5-6), Pittsburg girls 4x100 relay (46.42), Kaleb Pleis (San Ramon Valley), long jump (23-9½), Aydon Stefanopoulos (Los Gatos), 1,600 (4:06.68) FIFTH: Babalola-Buchango (St. Ignatius), 100 (10.56), Ben Stout (Amador Valley), high jump (6-7), Evan Usher (Woodside), shot put (58-4¾), discus (179-11) SIXTH: Khairee Baker (American Canyon), 100 (10.61), Bellarmine 4x800 relay (7:44.84), Devon Bertoli (Cardinal Newman), shot put (57-9¼), Emmanuel Fitzgerald (San Mateo), discus (177-10), Joshua Haven (Bellarmine), 300 hurdles (37.87), Kimiko Hirahara (Las Lomas), high jump (5-5), Annalise Horn (Redwood), long jump (18-9½), Tristan Kippes (Palo Alto), 800 (1:52.35), Grady Wachob (Benicia), high jump (6-7) SEVENTH: Anthony Dean (De La Salle), triple jump (47-6½), Daniela Hughes (Los Altos), triple jump (38-5½), McCuskey-Hay (St. Ignatius), 100 (11.63), Joshua Taylor (King's Academy), shot put (56-11½) EIGHTH: Amaya Bharadwaj (Palo Alto), 1,600 (4:48.14), Miles Cook (Sacred Heart Cathedral), 1,600 (4:10.73), Amaya DeFlorimonte (Bishop O'Dowd), triple jump (38-1), Case Jacobson (St. Francis), shot put (56-3½), McCuskey-Hay (St. Ignatius), 200 (24.31), Ryan Shen (Monta Vista), long jump (22-7¼), Lily Symon (Los Altos), 800 (2:10.24) Girls: Long Beach Wilson 46, Long Beach Poly 28, Santiago 28, Jurupa Valley 27, Carlsbad 25
Globe and Mail
6 days ago
- Business
- Globe and Mail
Top Real Estate in Los Altos, CA Achieves Multiple Overs, Through Strategic Home Prep and Targeted Marketing
Los Altos, CA - In today's highly competitive Silicon Valley housing market, Michael Sutton, a top Los Altos Real Estate Agent, continues to raise the bar. Leveraging smart home preparation, innovative digital marketing, and deep local expertise, Sutton recently secured multiple offers (each above asking price) on a home that, just three weeks prior, was in original condition. This sale demonstrates the powerful impact of focused preparation and strategic exposure. Sutton's approach goes far beyond traditional real estate tactics. His success lies in identifying cost-effective improvements that resonate with today's buyers – maximizing return on investment. Coupled with high-impact photography, home video, and targeted online marketing, Sutton creates the perfect combination that drives buyer interest and results. In this recent case, the home was transformed in just three weeks with a modest investment, generating five strong offers and ultimately selling for $1,500,000 – more than six times the sellers' upgrade budget. Based on Sutton's expert guidance, the sellers walked away with over $200,000 in added value, proving once again that the right strategy pays off. Known throughout the Bay Area for his deep market expertise, contractor background, and strong relationships with fellow agents, Sutton brings a decisive advantage to every transaction. As a seasoned Realtor in Los Altos and surrounding Silicon Valley communities, he provides buyers with early access to off-market properties and data-driven insights that give them the competitive advantage over the competition and guide them to confident, winning outcomes. To learn more about Michael Sutton and how he can help you achieve your Los Altos real estate goals, visit
Globe and Mail
14-05-2025
- Business
- Globe and Mail
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
- Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoing commercial planning in preparation for anticipated commercial launch in late 2025 - New data from patient surveys and patient-reported outcomes studies highlight adherence challenges for patients with hyperphosphatemia on dialysis and emphasize the market potential of OLC LOS ALTOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended March 31, 2025, and provided a business update. 'We are making incredible strides as we prepare for the potential FDA approval of oxylanthanum carbonate (OLC) so we can bring this treatment to people with chronic kidney disease (CKD) on dialysis as efficiently as possible,' said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. 'The need for our differentiated treatment, which offers high potency and a significantly reduced pill burden for people struggling to control hyperphosphatemia, has been further validated by new patient survey findings and patient-reported outcomes data. We remain dedicated to bolstering our commercial infrastructure as we strive to deliver a much-needed solution to patients and healthcare providers.' Key Highlights & Upcoming Milestones The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025, for OLC. Unicycive continues to prepare for the potential launch of OLC by building key functions, engaging directly with prescribers and other stakeholders, and supporting market access. Expanded awareness of OLC and its potential to address significant needs for CKD patients by publishing data and presentations at medical meetings. Recently, findings were presented at the National Kidney Foundation (NKF) Spring Clinical Meetings and the 2025 American Nephrology Nurses Association (ANNA) National Symposium from a patient survey conducted in partnership with the NKF. The survey included a total of 200 dialysis patients who identified excessive pill numbers, large pill sizes, and forgetfulness as the primary barriers to phosphate binder adherence. Patients also expressed a strong preference for medication regimens with fewer and smaller pills. New patient-reported outcomes data from the pivotal Phase 2 study of OLC were presented at the 2025 American Dialysis Conference (ADC) and the NKF Spring Clinical Meeting, which demonstrated that patients preferred OLC in comparison to their pre-trial phosphate binder medications and significantly enhanced patient satisfaction. Financial Results for the Quarter Ended March 31, 2025 Research and Development (R&D) expenses were $2.2 million for the three months ended March 31, 2025, compared to $6.8 million for the three months ended March 31, 2024. The decrease in research and development expenses was primarily due to decreased drug development costs. General and Administrative (G&A) expenses were $5.8 million for the three months ended March 31, 2025, compared to $2.4 million for the three months ended March 31, 2024. The increase was primarily due to increased consulting and professional services related to our commercial launch preparation. In addition to the above launch expenses, we continue to focus on the manufacturing of commercial supplies, as reflected in prepaid expenses and other current assets on our balance sheet which increased from $4.8 million as of December 31, 2024 to $7.6 million as of March 31, 2025. Other income was $8.6 million for the three months ended March 31, 2025, compared to an expense of $11.8 million for the three months ended March 31, 2024, primarily due to a decrease in the fair value of our warrant liability. Net income attributable to common stockholders for the three months ended March 31, 2025, was $0.5 million, compared to a net loss attributable to common stockholders of $21.2 million for the three months ended March 31, 2024. The net income for the three-month period ended March 31, 2025, was primarily due to a decrease in the fair value of our warrant liability. As of March 31, 2025, cash and cash equivalents totaled $19.8 million. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive's second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information about Unicycive, visit and follow us on LinkedIn and X. Forward-looking statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; our need to raise substantial additional capital in the future to fund our continuing operations and the development and commercialization of our current product candidates and future product candidates; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; risks related to delays in obtaining or failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; and our failure, or the failure of our third-party manufacturers, or their subcontractors, to comply with cGMPs or other applicable regulations, which could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Unicycive's Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Investor Contacts: Kevin Gardner LifeSci Advisors kgardner@ Media Contact: Rachel Visi Real Chemistry redery@ SOURCE: Unicycive Therapeutics, Inc. Unicycive Therapeutics, Inc. Balance Sheets (in thousands, except for share and per share amounts) As of As of December 31, March 31, 2024 2025 (Unaudited) Assets Current assets: Cash $ 26,142 $ 19,769 Prepaid expenses and other current assets 4,806 7,577 Total current assets 30,948 27,346 Right of use asset, net 645 518 Property, plant and equipment, net 75 83 Total assets $ 31,668 $ 27,947 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,058 $ 1,397 Accrued liabilities 3,562 4,143 Warrant liability 18,936 10,588 Operating lease liability - current 564 548 Total current liabilities 24,120 16,676 Operating lease liability - long term 117 - Total liabilities 24,237 16,676 Commitments and contingencies Stockholders' equity: Series A-2 Prime preferred stock, $0.001 par value per share - 21,338.01 Series A-2 Prime shares authorized at December 31, 2024 and March 31, 2025; 6,150.21 and 5,464.21 Series A-2 Prime shares issued and outstanding at December 31, 2024 and March 31, 2025, respectively - - Series B-2 preferred stock, $0.001 par value per share - 7,882 Series B-2 shares authorized at December 31, 2024 and March 31, 2025; 3,000 Series B-2 shares issued and outstanding at December 31, 2024 and March 31, 2025 - - Preferred stock: $0.001 par value per share - 9,846,891 shares authorized at December 31, 2024 and March 31, 2025; zero shares issued and outstanding at December 31, 2024 and March 31, 2025 - - Common stock, $0.001 par value per share - 400,000,000 shares authorized at December 31, 2024 and March 31, 2025; 113,842,364 and 119,749,743 shares issued and outstanding at December 31, 2024 and March 31, 2025, respectively 114 120 Additional paid-in capital 108,587 111,851 Accumulated deficit (101,270 ) (100,700 ) Unicycive Therapeutics, Inc. Statements of Operations (in thousands, except for share and per share amounts) (Unaudited) Three Months Ended March 31, 2024 2025 Operating expenses: Research and development $ 6,813 $ 2,171 General and administrative 2,391 5,818 Total operating expenses 9,204 7,989 Loss from operations (9,204) (7,989) Other income (expenses): Interest income 69 226 Interest expense (20) (15) Change in fair value of warrant liability (11,808) 8,348 Total other income (expenses) (11,759) 8,559 Net (loss) income (20,963) 570 Net (loss) income attributable to common stockholders, basic (21,171) 510 Net loss attributable to common stockholders, diluted (21,171) (6,214) Net (loss) income per share: Basic $ (0.61) $ - Diluted $ (0.61) $ (0.05) Weighted-average shares outstanding: Basic 34,912,692 116,818,811 Diluted 34,912,692 123,834,773
